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Abstract 
Background: Despite the significant impact of nosocomial infections on the morbidity and mortality of patients 
staying in the intensive care unit (ICU), no study over the past 20 years has focused specifically on VAP following 
secondary peritonitis. The objective of the present study was to determine in‑hospital mortality and epidemiological 
features attributed to ventilator‑associated pneumonia (VAP) following secondary peritonitis.
Methods: Prospective observational study involved 418 consecutive patients admitted in the ICU. Univariate and 
multivariate analyses were performed to identify risk factors associated with mortality and development of VAP.
Results: The incidence of VAP following secondary peritonitis was 9.6 %. Risk factors associated with the develop‑
ment of VAP were hospital‑acquired peritonitis, requiring >48 h of mechanical ventilation, and SOFA score. The onset 
of VAP was late in majority of patients. VAP was developed about 16.8 days after the initiation of the peritonitis. 
Etiological microorganisms responsible for the peritonitis were different than for VAP. The 90‑day in‑hospital mortality 
rate was 47.5 % of VAP patients. Independent factors associated with 30‑ to 90‑day in‑hospital mortality were VAP and 
SOFA.
Conclusions: In light of the impact on morbidity and mortality in the ICU, more attention should be given to the 
concurrent features among VAP and secondary peritonitis.
© 2016 Heredia‑Rodríguez et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made.
Background
Intra-abdominal infections (IAIs) are one of the most 
important causes of mortality in the intensive care unit 
(ICU) [1]. Secondary peritonitis constitutes 80–90  % of 
cases of IAIs and is originated from the microbiological 
infection of the gastrointestinal tract by the perforation 
of hollow organs, ischemia, malignancy, and periopera-
tive complications (anastomotic leakage, intraoperative 
contamination) [2, 3]. Secondary peritonitis can be clas-
sified in community-acquired and hospital-acquired, this 
latter associated with microorganisms presenting antibi-
otic resistance [2]. Mortality rate due to secondary peri-
tonitis ranges approximately between 10 and 20 % [4–6]. 
During the management, the clinical outcome of the 
patient may be critically compromised by the develop-
ment of nosocomial infections [7]. Ventilator-associated 
pneumonia (VAP) is a type of hospital-acquired pneu-
monia that is developed after at least 48 h of the patient’s 
intubation [8]. VAP is the most frequent of the nosoco-
mial infections occurring in the ICU, affecting to 9–27 % 
of all intubated patients [9]. The VAP is associated with 
an increased length of hospital stay, of about 4–13 days, 
and hospital costs [10–13]. In our knowledge, there are 
only in the literature three studies analyzing specifically 
clinical and epidemiological aspects of the develop-
ment of VAP following secondary peritonitis. The first 
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one was a retrospective study of 1982, which reported 
clinical outcomes of 143 patients with intra-abdominal 
abscesses, and revealing an incidence of VAP of 28.7  % 
of the patients, and a mortality rate attributed to VAP 
of 65.9  % [14]. The second one was a prospective study 
published in 1991 comparing clinical outcomes between 
nosocomial pneumonia and recurrent IAI [15]. The inci-
dence of VAP was 19.7 % of cases, and the mortality rates 
were 53 % for the group of patients with pneumonia and 
no recurrent IAI, and 75 % of those with both conditions. 
Finally, the third study, of 2006, included retrospectively 
medical records from 618,495 patients undergoing intra-
abdominal surgery [16]. From them, 13,292 patients 
developed subsequently pneumonia, and the mortality 
rate was of 10.7 %.
Although there are extensive studies analyzing second-
ary IAIs or VAP in the ICU, in our knowledge, studies 
focusing specifically on VAP following secondary peri-
tonitis are scarce and date mainly from two decades ago. 
Furthermore, there are some issues that remain being 
characterized, such as the lapse time between the start-
ing of the peritonitis and VAP onset, and whether or not 
the etiologic agents responsible for IAIs are the same that 
for VAP, which is critical for the selection of the empirical 
antibiotic therapy. Early VAP onset has been associated 
with better prognosis, while the late one has the highest 
mortality rates and is often associated with multidrug-
resistant microorganisms [8]. Our working hypothesis is 
that pneumonia increases the mortality in patients devel-
oping peritonitis. Therefore, the objective of the study 
was to determine in-hospital mortality and epidemio-
logical features attributed to VAP following secondary 
peritonitis.
Methods
This prospective observational study involved consecu-
tive patients admitted in the ICU of the clinical univer-
sity hospital of Valladolid between May 2008 and May 
2015 for the management of a secondary peritonitis. All 
patients, or family members, signed the written consent 
form to participate in the study. The collection of res-
piratory and blood samples, for microbiological examina-
tions, was required for the inclusion in the study. Patients 
presenting primary peritonitis or those who refused 
to sign the consent form were excluded from the study. 
One of the investigators made daily rounds in the ICU to 
identify eligible patients and determine the onset of VAP. 
Because of the observational nature of the study, investi-
gators did not interact with ICU treating physicians for 
the diagnosis or management of VAP. To test our work-
ing hypothesis, the primary endpoint was to evaluate 
whether or not VAP patients had a higher mortality rate 
than non-VAP patients. Secondary endpoints included 
the identification of variables potentially associated with 
in-hospital mortality and with the development of VAP. 
Procedures were performed in accordance with guide-
lines established by the hospital’s ethics committee and 
the Declaration of Helsinki.
Surgical procedures and microbiological management
The surgery was performed by an experienced and 
trained team following the guidelines for the treatment 
of complicated IAIs [17]. A laparoscopy or laparotomy 
was performed taking into account the diagnosis and 
the preference of the surgeon. Peritoneal fluid was sam-
pled to detect microbiological and mycological activ-
ity. The empirical antimicrobial therapy was started as 
soon as possible and consisted in the administration of 
amoxicillin/clavulanic acid or meropenem plus linezolid 
if community-acquired or hospital-acquired peritoni-
tis, respectively. Treatment against yeast infection was 
only considered in the case of organ failure. Ranitidine 
(50  mg intravenously every 12  h) was administered for 
gastric protection within the first 24  h of admission in 
the ICU. Mouthwashes with chlorhexidine were car-
ried out twice a day [18]. The adequacy of source control 
was confirmed by specialists in the ICU. The empiri-
cal antibiotic treatment for VAP was based on identify-
ing the most common pathogens associated with VAP 
in the ICU, following international guidelines, including 
the initial empirical treatment of methicillin-resistant S. 
aureus with linezolid or teicoplanin and of P. aeruginosa 
with at least one of the following antibiotics: imipenem, 
cefepime, or piperacillin–tazobactam, in association with 
amikacin or ciprofloxacin [19].
Diagnosis of VAP
According to the definition of the Centers for Disease 
Control and Prevention, VAP was diagnosed upon the 
presence of new and/or progressive pulmonary infil-
trates on a chest radiograph plus 2 or more of the follow-
ing criteria: fever (≥38.5  °C) or hypothermia (<36  °C), 
leukocytosis (≥12  ×  109/L), positive pleural fluid cul-
ture, purulent tracheobronchial secretions, or a reduc-
tion in PaO2/FIO2 of at least 15 % in the previous 48 h, 
a cavitating infiltrate, and/or evidence of bronchiolitis, 
neutrophilic alveolitis, and consolidation [20, 21]. The 
diagnosis also included those patients with a Pugin score 
greater than 6 [22]. The confirmation of the diagnosis 
included the isolation of at least one pathogenic microor-
ganism in significant bacterial counts, i.e., ≥103 colony-
forming units (CFU)/mL for protected specimen brush, 
≥104  CFU/mL in case of bronchoalveolar lavage, and 
≥105  CFU/mL for endotracheal aspiration. These cut-
offs were not modified in patients receiving antimicrobial 
therapy at the time of VAP diagnosis. Coagulase-negative 
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Staphylococcus, Corynebacterium spp., Candida spp., 
Viridans group streptococci, and Neisseria spp. were no 
considered pathogenic microorganisms. Special attention 
was given to species isolated from both peritoneal fluid 
and lungs.
Outcome variables and statistical analysis
In-hospital mortality (at 30  days, 30–90  days, and 
90  days) was differentiated from caused by the sever-
ity of the peritonitis or intraoperative and postoperative 
events. Patients were evaluated for VAP during mechani-
cal ventilation and within 48  h after extubation. Hospi-
tal-acquired infection was defined when occurred ≥48 h 
after admission. Early or late VAP onset was established 
depending on whether VAP was developed before or 
later the 4th day since the initiation of the peritonitis and 
the mechanical ventilation. Regarding the results of the 
antibiogram, the treatment was classified as adequate or 
inadequate. Multidrug resistance was considered when 
species showed resistance to at least three groups of anti-
biotics. Categorical variables were expressed as absolute 
and relative (%) frequencies, whereas continuous ones 
as the median and the standard deviation (SD) or the 
median and the interquartile range (IQR). Differences 
between groups were compared by using the t test, with 
continuous variables, and by Chi-square test or Fisher’s 
exact test, with categorical ones. A univariate analy-
sis, classifying patients in survivors and nonsurvivors, 
was also carried out to identify potential demographic 
and clinical factors associated with in-hospital mor-
tality. Kaplan–Meier analysis was performed to com-
pare overall survival regarding the development of VAP. 
Stepwise logistic regression analyses were performed 
to identify factors associated with in-hospital mortality 
and with the development of VAP (odds ratio, OR, and 
95  % confidence interval, 95  % CI). Independent vari-
ables introduced in the models were carefully selected to 
avoid confounding effects. The statistical significance was 
established for p ≤  0.05. All statistical procedures were 
performed with SPSS 19.0 software.
Results
Clinical and microbiological characteristics of patients
From a total of 418 patients presenting secondary peri-
tonitis, 40 subsequently did develop VAP (9.6  %) and 
378 did not (90.4  %; Table  1). The mean lapse time 
between the starting of the secondary peritonitis and 
the development of VAP was 16.8 ± 15.1 days (commu-
nity-acquired 14.6  ±  14.5  days and hospital-acquired 
21.8 ± 15.7 days). The VAP onset was early in 12 patients 
(30.0 %) and late in 28 (70.0 %; p < 0.001). The mean age 
of patients was 71.1 ± 11.0 years for those with VAP and 
70.0  ±  13.3  years for those without VAP. Septic shock 
was higher in VAP patients (82.5  %) than non-VAP 
(61.4 %), whereas severe sepsis was opposite, 17.5 versus 
38.6 % of patients, respectively. The infection was mainly 
hospital-acquired (70.0 %) in VAP patients, whereas com-
munity-acquired (52.1 %) in non-VAP. The main cause of 
peritonitis was bowel perforation in both groups (47.5 vs 
43.6 %, respectively). Colon/rectum (50.0 vs 40.7 %) and 
small bowel (17.5 vs 19.0 %) were the most frequent loca-
tions of the peritonitis. The acute physiology and chronic 
health evaluation II (APACHE II) score and the Sepsis-
Related Organ Failure Assessment (SOFA) score were 
significantly higher (p  =  0.007 and p  <  0.001) in VAP 
patients (15.95 ± 4.29 and 8.10 ± 2.50) than in non-VAP 
(13.65  ±  5.16 and 6.22  ±  2.46, respectively). A signifi-
cantly (p < 0.001) higher number of VAP patients (62.5 %) 
received low-dose steroid therapy than non-VAP patients 
(25.7 %). VAP patients required significantly (p < 0.001) 
more days of mechanical ventilation (8.91 ± 14.49 days) 
than non-VAP (2.61  ±  6.19  days). More than 48  h of 
mechanical ventilation was required in a higher num-
ber of VAP patients (47.5  %) than in non-VAP (20.4  %; 
p  <  0.001). The stay in the ICU and the hospital were 
significantly longer (p < 0.001) in VAP patients (median 
9.0 days; IQR 7.0–30.0 days; and median 45.0 days; IQR 
29.0–61.0  days, respectively) than in non-VAP (median 
3.0  days; IQR 1.0–7.0  days; and median 20.0  days; IQR 
11.0–34.0 days, respectively; Table 1). The most frequent 
species isolated from lungs of VAP patients were Acine-
tobacter spp. (45.0 % of patients), Klebsiella spp. (17.5 %), 
and P. aeruginosa (17.5 %) and from their peritoneal fluid 
were Enterococcus spp. (37.5  %), E. coli (35.0  %), Kleb-
siella spp. (25.0 %), and anaerobes (25.0 %; Table 2). All 
microorganisms given in Table 2 are associated with VAP. 
In lungs from non-VAP patients, the main species iso-
lated were anaerobes (0.3  % of patients) and from their 
peritoneal fluid were E. coli (28.6 %), anaerobes (27.5 %), 
and Enterococcus spp. (24.1 %). Only three patients pre-
sented the same species in the peritoneal fluid and in 
lungs (two patients with Klebsiella spp. and one with P. 
aeruginosa; p  <  0.001). VAP had a polymicrobial origin 
in four patients. None of the patients showed more than 
one VAP episode. Multidrug-resistant species were iso-
lated from 25 VAP patients (62.5 %; p = 0.02). Regarding 
the antibiogram, the antibiotic treatment was therefore 
adequate in 22 VAP patients (55.0 %; p = 0.37).
Relationship between secondary peritonitis, pneumonia, 
and mortality
Mortality at 30  days was not different between groups 
and however at 90  days was significantly higher 
(p  =  0.008) in VAP patients (45.0  %) than in non-VAP 
(5.8 %). Kaplan–Meier survival analysis revealed that the 
percentage of survival was different between VAP and 
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Table 1 Demographic and  clinical characteristics 24  h after  the admission in  the ICU in  patients presenting secondary 
peritonitis regarding the subsequent development of ventilator-associated pneumonia
VAP patients (n = 40) Non-VAP patients (n = 378) P value
Age (mean years ± SD) 71.1 ± 11.0 70.0 ± 13.3 0.61
Sex male [n (%)] 31 (77.5) 217 (57.4) 0.014
Comorbidities [n (%)]
 Diabetes mellitus 33 (82.5) 283 (74.3) 0.02
 Hypertension 21 (52.5) 194 (51.3) 0.81
 Malignant neoplasm 16 (40.0) 168 (44.4) 0.63
 Obesity 5 (12.5) 52 (13.8) 0.83
 Chronic renal failure 5 (12.5) 34 (9.0) 0.46
 Immunosuppression 1 (2.5) 13 (3.4)
 Liver disease 2 (5.0) 11 (2.9) 0.46
 Acute renal failure, dialysis 2 (5.0) 7 (1.9)
Postoperative status [n (%)] 0.001
 Septic shock 33 (82.5) 232 (61.4)
 Severe sepsis 7 (17.5) 146 (38.6)
Type of infection [n (%)] 0.007
 Community‑acquired 12 (30.0) 181 (47.9)
 Hospital‑acquired 28 (70.0) 197 (52.1)
Etiology of peritonitis [n (%)] 0.72
 Bowel perforation 19 (47.5) 165 (43.6)
 Anastomotic leakage 6 (15.0) 74 (19.6)
 Biliary pathology 6 (15.0) 44 (11.6)
 Ischemia 3 (7.5) 34 (9.0)
 Abdominal Abscess 2 (5.0) 36 (9.5)
 Pancreatitis 4 (10.0) 18 (4.8)
 Bladder perforation 0 (0.0) 3 (0.8)
 Uterine perforation 0 (0.0) 3 (0.8)
 Vesical perforation 0 (0.0) 4 (1.1)
Location of the peritonitis† [n (%)] 0.75
 Colon/rectum 20 (50.0) 154 (40.7)
 Small bowel 7 (17.5) 72 (19.0)
 Biliary pathology 5 (12.5) 60 (15.9)
 Stomach and duodenum 1 (2.5) 31 (8.2)
 Pancreas 4 (10.0) 23 (6.1)
 Appendix 2 (5.0) 16 (4.2)
 Bladder 0 (0.0) 10 (2.6)
 Various 1 (2.5) 8 (2.1)
 Uterus/fallopian tubes 0 (0.0) 4 (1.1)
Clinical score
 APACHE II (mean ± SD) 15.95 ± 4.29 13.65 ± 5.16 0.007
 SOFA (mean ± SD) 8.10 ± 2.50 6.22 ± 2.46 <0.001
Postoperative management
 Low‑dose steroid therapy [n (%)] 25 (62.5) 97 (25.7) <0.001
 Blood transfusions, units 3.50 ± 7.44 2.37 ± 4.89 0.192
 Politransfusion (>10 units) [n (%)] 6 (15.0) 45 (11.9) 0.57
Mechanical ventilation
 Total duration (days ± SD) 8.91 ± 14.49 2.61 ± 6.19 <0.001
 Patients requiring >48 h [n (%)] 19 (47.5) 77 (20.4) <0.001
Time for VAP onset (mean days ± SD) 16.8 ± 15.1 –
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non-VAP patients (log rank =  5.289; p =  0.021; Fig.  1), 
indicating higher values for non-VAP patients. Both sur-
vival curves diverged after the day 40th of admission in 
the ICU.
Factors associated with in-hospital mortality 
and development of VAP
By classifying patients in survivors (n = 304, 72.7 %) and 
nonsurvivors (n  =  114, 27.3  %), the univariate analysis 
demonstrated that in-hospital mortality was significantly 
associated with 19 demographic or clinical variables 
(Table  3). The logistic regression model indicated that 
independent factors associated with 30-day in-hospi-
tal mortality were age (OR 1.038; CI 95  % 0.003–1.013; 
p  =  0.003), SOFA (OR 1.329, CI 95  % 0.0001–1.171; 
p < 0.001), and severe sepsis/septic shock (OR 3.105; CI 
95 % 0.013–1.271; p = 0.013). Stepwise logistic regression 
model to identify independent factors associated with in-
hospital mortality at 30, 30–90, and 90  days in patients 
with secondary peritonitis is given in Table 4. Independ-
ent factors associated with 30- to 90-day in-hospital 
mortality were SOFA (OR 1.373, CI 95 % 0.0001–1.151; 
p  <  0.001), and VAP (OR 3.777, CI 95  % 0.006–1.475; 
p  =  0.006). Factors associated with 90-day in-hospi-
tal mortality were age (OR 1.036; CI 95  % 0.002–1.013; 
p  =  0.002), SOFA (OR, 1.247, CI 95  % 0.006–1.065; 
p =  0.006), creatinine (OR 1.351; CI 95  % 0.042–1.011; 
p  =  0.042), and severe sepsis/septic shock (OR 2.967; 
VAP ventilator‑associated pneumonia, SD standard deviation, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sepsis‑Related Organ Failure 
Assessment, ICU intensive care unit, IQR interquartile range
† In some patients, the infection extended into more than one location
Table 1 continued
VAP patients (n = 40) Non-VAP patients (n = 378) P value
Clinical outcome
 Stay at ICU, median days (IQR) 9.0 (7.0–30.0) 3.0 (1.0–7.0) <0.001
 Total stay at the hospital, median days (IQR) 45.0 (29.0–61.0) 20.0 (11.0–34.0) <0.001
 Mortality after 30 days [n (%)] 7 (17.5) 76 (20.1) 0.69
 Mortality after 90 days [n (%)] 18 (47.5) 96 (25.4) 0.008
Table 2 Microorganisms isolated from lungs and peritoneal fluid associated with VAP in patients with secondary perito-
nitis
Percentages may sum more than 100 % because more than one pathogen could have been found in an individual patient
Lungs Peritoneal fluid
VAP patients (n = 40) Non-VAP patients (n = 378) VAP patients (n = 40) Non-VAP patients (n = 378)
Gram‑positive cocci
 Methicillin susceptible  
Staphylococcus aureus
6 (15.0) 0 (0.0) 1 (2.5) 8 (2.1)
 Methicillin‑resistant  
Staphylococcus aureus
2 (5.0) 0 (0.0) 0 (0.0) 2 (0.5)
 Staphylococcus epidermidis 0 (0.0) 0 (0.0) 7 (17.5) 26 (6.9)
  Other Staphylococcus spp. 2 (5.0) 0 (0.0) 0 (0.0) 16 (4.2)
 Streptococcus spp. 0 (0.0) 0 (0.0) 4 (10.0) 33 (8.7)
 Enterococcus spp. 1 (2.5) 0 (0.0) 15 (37.5) 91 (24.1)
 Other 0 (0.0) 0 (0.0) 4 (10.0) 10 (2.6)
Gram‑negative bacilli
 Klebsiella spp. 7 (17.5) 0 (0.0) 10 (25.0) 27 (7.1)
 Enterobacter spp. 1 (2.5) 0 (0.0) 6 (15.0) 25 (6.6)
 Escherichia coli 4 (10.0) 0 (0.0) 14 (35.0) 108 (28.6)
 Pseudomonas aeruginosa 7 (17.5) 0 (0.0) 6 (15.0) 3 (0.8)
 Acinetobacter spp. 18 (45.0) 1 (0.3) 2 (5.0) 5 (1.3)
 Other Enterobacteriaceae 2 (5.0) 0 (0.0) 0 (0.0) 8 (2.1)
Anaerobes 1 (2.5) 1 (0.3) 10 (25.0) 104 (27.5)
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CI 95  % 0.004–1.402; p  =  0.004). Finally, independent 
factors associated with the development of VAP were 
hospital-acquired peritonitis (OR 2.873; CI 95 % 1.299–
6.369; p = 0.009), SOFA (OR 1.325; CI 95 % 1.126–1.559; 
p = 0.001), and requiring >48 h of mechanical ventilation 
(OR 2.359; CI 95 % 1.074–5.181; p = 0.032).
Discussion
Despite the significant impact of nosocomial infections 
on morbidity and mortality of patients staying in the ICU, 
no study over the last 20 years has determined the clini-
cal, epidemiological, and microbiological features of VAP 
following secondary peritonitis. Therefore, the goal of the 
present study was to complete and update such lacking 
information. The most relevant results from our study 
included: (1) an updated incidence value of VAP of 9.6 %; 
(2) risk factors associated with the development of VAP 
including hospital-acquired peritonitis, requiring >48  h 
of mechanical ventilation, and SOFA score; (3) mainly 
late onset of VAP, and caused by multidrug-resistant 
microorganisms intrinsically different for each condition; 
(4) the 90-day in-hospital mortality rate of 47.5 % of VAP 
patients; and (5) independent factors associated with 30- 
to 90-day in-hospital mortality including VAP and SOFA 
score.
Overall incidence of VAP reported in our study 
was 9.6  % of patients who underwent surgery due to 
Fig. 1 Kaplan–Meier analysis showing the percentage of survival 
between patients with and without ventilator‑associated pneumonia
Table 3 Significant demographic and clinical variables potentially associated with in-hospital mortality
SD standard deviation, ICU intensive care unit, HCO3
− bicarbonate, VAP ventilator‑associated pneumonia, IQR interquartile range
Nonsurvivors (n = 114) Survivors (n = 304) P value
Age (mean years ± SD) 74.69 ± 10.43 68.38 ± 13.58 0.006
Comorbidities [n (%)]
 Chronic renal failure 21 (18.4) 18 (5.9) <0.001
 Acute renal failure, dialysis 3 (2.6) 6 (2.0) <0.001
 Immunosuppression 11 (9.6) 4 (1.3) <0.001
Postoperative status 0.001
 Severe sepsis 12 (10.5) 139 (45.7)
 Septic shock 100 (87.7) 163 (53.6)
Biochemical parameters at ICU (mean ± SD)
 Sodium (mEq/L) 137.64 ± 6.8 136.05 ± 4.81 <0.001
 Creatinine (mg/dL) 2.18 ± 1.71 1.21 ± 0.77 <0.001
 Lactate (mmol/L) 34.90 ± 26.16 24.13 ± 19.28 0.005
 Procalcitonin (ng/mL) 24.48 ± 36.42 16.27 ± 30.28 0.043
 HCO3
− (mEq/L) 20.42 ± 7.28 21.73 ± 5.52 0.030
Postoperative management
 Low‑dose steroid therapy 25 (21.9) 97 (31.9) <0.001
 Blood transfusions, units 4.43 ± 6.90 1.74 ± 4.16 <0.001
 Politransfusion (>10 units) [n (%)] 26 (22.8) 25 (8.2) <0.001
Mechanical ventilation
 Total duration (days ± SD) 7.38 ± 11.70 1.69 ± 4.48 <0.001
 Patients requiring >48 h [n (%)] 50 (43.9) 46 (15.1) <0.001
Clinical outcome
 Stay at ICU, median days (IQR) 8.0 (3.8–14.3) 3.0 (1.0–6.0) <0.001
 Total stay at the hospital, median days (IQR) 21.0 (9.3–43.8) 21.0 (12.3–35.0) 0.004
 VAP 18 (15.8) 22 (7.2) 0.008
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peritonitis, a value significantly lower than previous stud-
ies, ranging between 20 and 30  % [14, 15]. A possible 
explanation may derive from the fact that, in our study, 
VAP included both hospital- and community-acquired 
cases; however, previous studies only included hospital-
acquired cases, which are associated with higher inci-
dence rates. Moreover, the reduction in the impact of 
VAP over the years may be a result of the implementa-
tion of effective preventive strategies in the ICU, such as 
the Spanish national VAP prevention bundle called “zero 
VAP,” based on good general practices for control of the 
infection and pathogenic-tailored strategies [23, 24]. The 
International Nosocomial Infection Control Consortium 
reported a decrease in incidence from 15 to 8 % in a sur-
veillance study conducted from 2004 to 2009 [25, 26].
There are many factors potentially associated with the 
development of VAP, including preexisting medical con-
ditions in the patient (such as immunosuppression or 
chronic obstructive lung disease), body position, level 
of consciousness, nasotracheal intubation, duration of 
the mechanical ventilation, ventilator circuit-related fac-
tors, enteral nutrition, or personnel-related factors (such 
as inadequate hand hygiene or change in gloves between 
patients) [12, 27, 28]. In our study, hospital-acquired 
peritonitis, requiring >48  h of mechanical ventilation, 
and SOFA score were independent factors for VAP devel-
opment. The duration of ventilation has been positively 
correlated with the development of VAP, although this 
potential risk seems not to be constant over the time [12]. 
Specifically, the risk of VAP has been estimated in 3  % 
per day during the first week of mechanical ventilation, 
2 % in the second week, and 1 % in the subsequent weeks 
[27]. A high SOFA score at admission in the ICU has 
been associated with mortality in VAP patients [29]; for 
this reason, a high score in multiple organ dysfunction, 
concomitant with a probably immunosuppression status 
and/or other underlying medical conditions, may be a 
cause for the development of such opportunistic infec-
tion. Similarly, hospital-acquired peritonitis is associated 
with microorganisms presenting antibiotic resistance, 
poor outcomes, and longer stays in the hospital, com-
pared with community-acquired peritonitis, which may 
explain its correlation with the development of VAP [2].
The onset of VAP was late in the majority of patients. 
More than 90  % of cases of VAP occur within the first 
10  days of the intubation [30]. VAP was also developed 
about 16.8  days after the initiation of the peritonitis. A 
high percentage of the microorganisms responsible of 
VAP were multidrug resistant (62.5  %). Regarding the 
antibiogram, almost half of patients (55.0 %) received an 
adequate treatment. The low number of patients receiv-
ing adequate antibiotic treatment may be a consequence 
of: (1) the late onset of pneumonia (16.8  ±  15.1  days) 
since the initiation of the peritonitis. At this time, 
patients had received other antibiotic treatments for 
the peritonitis. (2) the peritonitis was the primary tar-
get of the antibiotic treatment; VAP was not so. It has 
been demonstrated that patients who receive inadequate 
empiric antibiotic treatment have longer hospital stays, 
higher rates of abscesses, and mortality [31]. For this rea-
son, attention should be given to the antibiogram of each 
respective center, selecting adequate antibiotics taken 
into account potential multidrug-resistant microorgan-
isms [1]. The high rate of multidrug resistance found in 
our study may be correlated with the higher proportion 
of patients presenting late-onset VAP. In general, etiolog-
ical microorganisms responsible for the peritonitis were 
different than for VAP, which is consistent with previous 
studies [6].
According to published studies, mortality rates attrib-
utable to VAP range between 53 and 75 % [14, 15]. Since 
clinical outcomes depend on the length of the stay in the 
ICU, one goal of our study was to investigate differences in 
in-hospital mortality at different endpoints (30, 30–90, and 
90 days). VAP patients showed a significant higher mortal-
ity rate and longer hospital stay than non-VAP. The 90-day 
mortality was 47.5 % of VAP patients, a value slightly lower 
than previous studies. Similar to the incidence, there is a 
decreasing tendency in the mortality rate as a result of the 
implementation of preventive strategies [22, 25]. In our 
Table 4 Logistic regression models to  identify factors 
associated with  in-hospital mortality and  with the devel-
opment of VAP
OR odds ratio, CI confidence interval, SOFA Sepsis‑Related Organ Failure 
Assessment, VAP ventilator‑associated pneumonia
OR 95 % CI P value
In‑hospital mortality
 30‑day in‑hospital mortality
  Age (years) 1.038 1.013–1.064 0.003
  SOFA score 1.329 1.171–1.510 <0.001
  Severe sepsis/septic shock 3.105 1.271–7.588 0.013
 30‑ to 90‑day in‑hospital mortality
  SOFA score 1.373 1.151–1.637 <0.001
  VAP 3.777 1.475–9.671 0.006
 90‑day in‑hospital mortality
  Age (years) 1.036 1.013–1.060 0.002
  SOFA score 1.247 1.065–1.461 0.006
  Creatinine (mg/dL) 1.351 1.011–1.805 0.042
  Severe sepsis/septic shock 2.967 1.402–6.278 0.004
Development of VAP
 Hospital‑acquired peritonitis 2.873 1.299–6.369 0.009
 SOFA score 1.325 1.126–1.559 0.001
 Requiring >48 h of mechanical  
ventilation
2.359 1.074–5.181 0.032
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study, the mortality rate was actually quite high, even in 
the non-VAP cohort, for secondary peritonitis. The recent 
multicenter STOP-IT trial has reported a mortality rate 
of 1.2  % for patients with complicated intra-abdominal 
infection [32]. Although this study cohort did have a much 
higher rate of septic shock and severe sepsis than that our 
study, most recent severe sepsis and septic shock studies 
have reported mortality rates of approximately 25 %. Risk 
factors associated with in-hospital mortality included VAP 
and SOFA score, although the univariate analysis revealed 
both VAP and stay at ICU as significant risk factors asso-
ciated with mortality. VAP was only significant for 30- to 
90-day in-hospital mortality. According to the literature, 
the development of VAP is associated with the percentage 
of nonsurvivors and survivors in a rate 2:1. It is interest-
ing to note that Kaplan–Meier curves showed a significant 
divergence in survival likelihood since approximately the 
day 40th after admission in the ICU. Among the extensive 
studies evaluating the risk factors associated with worse 
outcomes and mortality for secondary peritonitis [31, 
33–35], none of them have included VAP in their analy-
ses. One possible reason to omit it might derive from the 
fact that VAP is intrinsically associated with the stay in 
the ICU, whatever the underlying condition of the patient. 
Nevertheless, results of our study highlight the importance 
of including VAP as a factor involved in the 30- to 90-day 
in-hospital mortality of patient with secondary peritonitis. 
Our present study had some limitations. One of them was 
that the study was performed in a single center. A multi-
center study might have strengthen results obtained in 
the study and have reduced factors intrinsically associated 
with the center, such as the empiric antibiotic treatment 
or the spectrum of nosocomial pathogenic microorgan-
isms. Another limitation of the study was the low num-
ber of patients developing VAP (40). Although similar to 
the sample size of the literature, a large cohort of patients 
might also have strengthen our results and diminish inter-
individual differences.
Conclusion
In light of the impact on morbidity and mortality in the 
ICU, more attention should be given to the concurrent 
features among VAP and secondary peritonitis. Addi-
tional prospective studies, involving large cohort of 
patients, are required to corroborate these results.
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